利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

48 条记录 (耗时 0.044 秒)

    Systems and methods for delivery of drugs
    3.
    发明申请
    Systems and methods for delivery of drugs 审中-公开
    用于输送药物的系统和方法

    公开(公告)号：US20090263346A1

    公开(公告)日：2009-10-22

    申请号：US12315876

    申请日：2008-12-04

    申请人： David Taft ,  Steven Bitler ,  Qiang Zheng ,  Stelios Tzannis ,  Adam Bell ,  Wei-Guo Dai ,  Sandra Ottensmann

    发明人： David Taft ,  Steven Bitler ,  Qiang Zheng ,  Stelios Tzannis ,  Adam Bell ,  Wei-Guo Dai ,  Sandra Ottensmann

    IPC分类号： A61K47/48 ,  A61P25/18

    CPC分类号： A61K9/146 ,  A61K9/0019 ,  A61K9/0024

    摘要： Systems and methods for delivering drugs. Crystalline polymeric systems, referred to as CYC carriers, are associated with the drugs, through chemical bonding or through physical association. The crystallinity of the CYC carriers results from the presence of crystallizable side chains, for example long chain n-alkyl moieties, which results in relatively low and sharp melting temperatures. One class of CYC carriers, referred to as CYSC polymers, have a majority of the crystallizable side chains pendant from the polymer backbone. Another class of CYC carriers, referred to as ECC polymers, have a majority of the crystallizable side chains attached to terminal units of the polymer backbone. The ECC polymers can for example be obtained by modification of PLGA polymers. The CYC carriers in another class are non-polymeric. Some CYC carriers, referred to as CYC assemblies, have enhanced crystallinity as a result of the physical association of crystallizable moieties which are present in different types of molecule, for example between a polymer containing crystallizable moieties and a monomer containing crystallizable moieties. Preferably the CYC carrier is bioerodable.

    摘要翻译： 递送药物的系统和方法。 称为CYC载体的结晶聚合体系通过化学键合或通过物理缔合与药物相关联。 CYC载体的结晶度来自可结晶侧链的存在，例如长链正烷基部分，这导致相对低的和尖锐的熔融温度。 称为CYSC聚合物的一类CYC载体具有从聚合物主链悬挂的大部分可结晶侧链。 称为ECC聚合物的另一类CYC载体具有连接至聚合物主链末端单元的大部分可结晶侧链。 ECC聚合物可以例如通过改性PLGA聚合物获得。 另一类的CYC载体是非聚合物。 一些称为CYC组件的CYC载体由于存在于不同类型分子中的可结晶部分的物理结合而具有增强的结晶度，例如在含可结晶部分的聚合物和含可结晶部分的单体之间。 CYC载体优选是可生物侵蚀的。

    Lipid formulations for spontaneous drug encapsulation
    4.
    发明申请
    Lipid formulations for spontaneous drug encapsulation 审中-公开
    用于自发药物包封的脂质制剂

    公开(公告)号：US20050214224A1

    公开(公告)日：2005-09-29

    申请号：US10982191

    申请日：2004-11-04

    申请人： Jeffry Weers ,  Thomas Tarara ,  Stelios Tzannis

    发明人： Jeffry Weers ,  Thomas Tarara ,  Stelios Tzannis

    IPC分类号： A61K9/00 ,  A61K9/127 ,  A61K9/16 ,  A61L9/04 ,  A61M15/00

    CPC分类号： A61K9/0075 ,  A61K9/127 ,  A61K9/1617 ,  A61M15/0028 ,  A61M15/0041 ,  A61M2202/064

    摘要： A pharmaceutical formulation for pulmonary administration is disclosed. The pharmaceutical formulation comprises a lipid component and an active agent, wherein the pharmaceutical formulation has a liquid phase transition temperature of less than or equal to 37° C. when hydrated and a liquid phase transition temperature of greater than 57° C. when non-hydrated, whereby the lipid component spontaneously encapsulates and/or entraps the active agent when the pharmaceutical formulation is administered to the lungs. A targeting agent may also be provided. In one version, the pharmaceutical formulation is useful to treat an infection, such as an inhalation anthrax infection.

    摘要翻译： 公开了一种用于肺部给药的药物制剂。 药物制剂包含脂质组分和活性剂，其中当水合时，药物制剂的液相转变温度小于或等于37℃，液相转变温度大于57℃时， 当药物制剂施用于肺时，脂质组分自发地包封和/或捕获活性剂。 还可以提供靶向剂。 在一个版本中，药物制剂可用于治疗感染，例如吸入性炭疽感染。

    Systems and methods for delivery of materials
    5.
    发明授权
    Systems and methods for delivery of materials 有权
    材料交付的系统和方法

    公开(公告)号：US08524259B2

    公开(公告)日：2013-09-03

    申请号：US12746178

    申请日：2008-12-03

    申请人： David D. Taft ,  Steven Bitler ,  Qiang Zheng ,  Stelios Tzannis ,  Adam Bell ,  Wei-Guo Dai ,  Sandra N. Ottensmann ,  Natarajan Balachander

    发明人： David D. Taft ,  Steven Bitler ,  Qiang Zheng ,  Stelios Tzannis ,  Adam Bell ,  Wei-Guo Dai ,  Sandra N. Ottensmann ,  Natarajan Balachander

    IPC分类号： C08G63/06

    CPC分类号： A61K9/0024 ,  A61K9/0019 ,  A61K9/146

    摘要： Systems and methods for delivering release materials, for example drugs and other bioactive materials. Crystalline polymeric systems, referred to as CYC carriers, are associated with the release materials, through chemical bonding or through physical association. The crystallinity of the CYC carriers results from the presence of crystallizable side chains, for example long chain n-alkyl moieties, which results in relatively low and sharp melting temperatures. One class of CYC carriers, referred to as CYSC polymers, have a majority of the crystallizable side chains pendant from the polymer backbone. Another class of CYC carriers referred to as ECC polymers, have a majority of the crystallizable side chains attached to terminal units of the polymer backbone. The ECC polymers can for example be obtained by modification of PLGA polymers. The CYC carriers in another class of non-polymeric. Some CYC carriers, referred to as CYC assemblies, have enhanced crystallinity as a result of the physical association of crystallizable moieties which are present in different types of molecule, for example between a polymer containing crystallizable moieties and a monomer containing crystallizable moieties. For some uses, particularly the delivery of drugs, a bioerodable CYC carrier is preferably used.

    摘要翻译： 用于输送释放材料的系统和方法，例如药物和其他生物活性材料。 称为CYC载体的结晶聚合体系通过化学键合或通过物理缔合与释放材料相关联。 CYC载体的结晶度来自可结晶侧链的存在，例如长链正烷基部分，这导致相对低的和尖锐的熔融温度。 称为CYSC聚合物的一类CYC载体具有从聚合物主链悬挂的大部分可结晶侧链。 称为ECC聚合物的另一类CYC载体具有连接至聚合物主链末端单元的大部分可结晶侧链。 ECC聚合物可以例如通过改性PLGA聚合物获得。 CYC载体在另一类非聚合物中。 一些称为CYC组件的CYC载体由于存在于不同类型分子中的可结晶部分的物理结合而具有增强的结晶度，例如在含可结晶部分的聚合物和含可结晶部分的单体之间。 对于一些用途，特别是药物的递送，优选使用生物侵蚀性CYC载体。